Non-Small Cell Lung Cancer MedDRA version: 17.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Code: Ro 547-9599/F01
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: n.a.
CAS Number: 1448327-63-6
Current Sponsor code: RO5479599
Other descriptive name: huMA
Sponsors
F. Hoffmann- La Roche Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Age >/= 18 years - ECOG performance status (PS) 0 - 1 - Histologically confirmed squamous NSCLC patients - Locally advanced or metastatic (stage IIIB or IV) squamous NSCLC - No prior systemic chemotherapy, targeted therapy for metastatic NSCLC - Evidence of at least one radiologically measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 - Adequate hematological, liver and renal function - Use of highly effective contraception Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 35 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 18
Exclusion criteria
Exclusion criteria: - Concurrent therapy with any other investigational drug - History or clinical evidence of central nervous system (CNS) primary tumors or metastases - Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus and/or significant cardiovascular disease or uncontrolled infection - Any other diseases, metabolic dysfunction, a physical examination finding or a clinical laboratory finding, giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug - Major surgery or significant traumatic injury < 28 days prior to the first study treatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment - Pregnant or breast-feeding women - History of other malignancies that could affect compliance with protocol or interpretation of results. Patients with malignancies diagnosed more than five years prior to study day one, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer are generally eligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: • To evaluate the safety and tolerability of RO5479599 in combination with carboplatin and paclitaxel • To estimate the efficacy of RO5479599 in combination with carboplatin and paclitaxel, as measured by the objective response rate (ORR, defined as complete response [CR] rate + partial response [PR] rate);Secondary Objective: • To evaluate patients for progression-free survival (PFS) and overall survival (OS) • To evaluate disease control rate (DCR, defined as ORR + stable disease [SD] rate) • To describe the PK of RO5479599 in combination with carboplatin and paclitaxel;Primary end point(s): 1. Incidence of adverse events 2. Objective response rate (ORR), defined as complete response (CR) rate + partial response (PR) rate at 6 weeks;Timepoint(s) of evaluation of this end point: 1. Up to 30 months 2. 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. Progression-free survival (PFS) 2. Outcome Measure: Overall survival (OS) 3. Outcome Measure: Disease control rate (DCR) 4. Pharmacokinetic parameters derived from serum RO5479599 concentrations ;Timepoint(s) of evaluation of this end point: Up to 30 months | — |
Countries
Canada, Denmark, France, Germany, Korea, Republic of, Netherlands, Spain, United Kingdom, United States
Contacts
Public ContactTrial Information Support Line-TISL
F.Hoffmann-La Roche Ltd.
Outcome results
None listed